Considering Wegovy for Weight Loss? South Korea's Drug Safety Ministry Warns It Is Not for Everyone
South Korea’s Ministry of Food and Drug Safety issued a strong warning on July 8 against the misuse and abuse of GLP-1 class anti-obesity...
Search results for "GLP-1 obesity drugs"
The GLP-1 Paradox: Wegovy and Mounjaro Patients Shed Weight, but Walk Less
"First I’ll lose the weight, and then I’ll start exercising."It is a thought shared by almost anyone starting highly effective obesity medications...
GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use
A new study suggests that the long-term administration of GLP-1 receptor agonists—the class of anti-obesity medications...
The Surprising Life-Saving Potential of Weight Loss Meds in Diabetic Foot Care
GLP-1 receptor agonists (such as Wegovy and Ozempic), currently dominating the headlines as weight loss medications,...
Samsung Biologics Bets 2.7 Trillion Won on Peptides in South Korea’s Largest Biotech M&A Deal
Samsung Biologics is making a major push into peptide-based medicines—widely used in weight-loss and diabetes...
Maximizing Weight Loss vs. Protecting the Heart: The Paradox of Modern Anti-Obesity Drugs
As global demand for anti-obesity medications surges, a fierce pharmaceutical race is underway to develop...
Resistance in the Genes: Why Popular Obesity Drugs Don’t Work for Everyone
GLP-1 receptor agonists like Wegovy and Mounjaro have fundamentally reshaped the treatment of diabetes and obesity.
Can Wegovy and Mounjaro Reduce Cancer Risk?
Global obesity experts have proposed a large-scale, long-term follow-up study to verify whether the use of modern...
"It Wasn't Just Weight Loss That Improved My Knees"...Ozempic Study Confirms Cartilage 'Metabolic Changes'
"Please lose some weight. " This is a common phrase heard when visiting a hospital for knee pain.
GLP-1 Drugs and Bone Health: Studies Highlight Fracture Risks in Elderly Patients
The GLP-1 receptor agonist class of drugs, widely used for the treatment of obesity and type 2 diabetes, has...